首页> 外文期刊>Journal of substance abuse treatment >Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre
【24h】

Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre

机译:与参加基于针头注射器计划的初级保健中心的注射吸毒者的丙型肝炎专业治疗服务的联系

获取原文
获取原文并翻译 | 示例
           

摘要

Injecting drug users (IDUs), the key risk population for hepatitis C virus (HCV) infection, constitute just a small proportion of HCV treatment clients. This study describes an HCV treatment assessment model developed by an inner-city IDU-targeted primary healthcare (PHC) facility and, using a retrospective clinical audit, documents predictors of successful referrals to a tertiary liver clinic. Between July 2006-December 2010, 479 clients attended the PHC, of whom 353 (74%) were screened for HCV antibody. Sixty percent (212/353) tested positive, of whom 93% (197/212) were screened for HCV-RNA with 73% (143/197) positive. Referrals to a tertiary liver clinic were provided to 96 clients, of whom 68 (71%) attended. Eleven clients commenced antiviral therapy (AVT), with seven achieving sustained virological responses by December 2010. Clients who had not recently injected drugs and those with elevated ALT levels were more likely to attend the referrals, while those not prescribed psychiatric medications were more likely to commence AVT. The relatively high uptake of referrals, the number of individuals commencing AVT and final treatment outcomes are reasonably encouraging, highlighting the potential of targeted PHC services to facilitate reductions in liver disease burden among IDUs. (C) 2012 Elsevier Inc. All rights reserved.
机译:注射毒品使用者(IDU)是丙型肝炎病毒(HCV)感染的主要风险人群,仅占HCV治疗客户的一小部分。这项研究描述了由以城市为IDU的城市为目标的初级医疗保健(PHC)机构开发的HCV治疗评估模型,并使用回顾性临床审计记录了成功转诊至三级肝病诊所的预测因素。在2006年7月至2010年12月之间,有479位客户参加了PHC,其中353位(74%)接受了HCV抗体筛查。 60%(212/353)呈阳性,其中93%(197/212)呈HCV-RNA筛查,其中73%(143/197)呈阳性。向96位客户提供了转诊至第三级肝脏诊所的服务,其中68位(71%)参加了该服务。 11位客户开始抗病毒治疗(AVT),到2010年12月,有7位客户获得了持续的病毒学应答。近期未注射药物和ALT水平升高的客户更有可能参加转诊,而未开处方精神药物的客户则更有可能接受转诊。开始AVT。推荐人的相对较高的接受率,开始AVT的人数和最终治疗的结果都令人鼓舞,这突显了有针对性的PHC服务在减轻IDU肝病负担方面的潜力。 (C)2012 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号